One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
SAB Biotherapeutics, Inc.
SABS · NCM · Healthcare · Biotechnology
Current price
$2.53
52-week range
$2.10 - $5.15
Market cap
$230.20M
Balance sheet
Healthy
-203.41x Concerning
Net cash $97.50M. Interest coverage shows how many times profit covers the interest bill.
What stands out
0 Rewards
2 Risks
0 rewards · 2 risks
- Risk Insider ownership is only 0.7% (peer median: 12.5%).
- Risk Return on equity was -11.3% last year — the company lost money on shareholders' equity.
What this company does
SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc. is a company working on new medicines, mainly for immune system problems like type 1 diabetes. Their main effort is a medicine called SAB-142, which is currently being tested in people to see if it can help manage autoimmune type 1 diabetes. Because they are still developing their medicines, they don't have any products for sale yet, and their money primarily comes from investors funding this research.
How the company got here
SAB Biotherapeutics was founded in 2014, emerging from a merger of two other companies. It's a clinical-stage biopharmaceutical company, meaning it's focused on developing new medicines that are still being tested in human trials. The company went public in 2021 through a special purpose acquisition company (SPAC) merger, which is a way for private companies to become publicly traded without a traditional initial public offering (IPO). This move provided them with capital to advance their research and development efforts. SAB Biotherapeutics has also received significant funding from government contracts and grants, particularly for programs related to infectious diseases like COVID-19 and influenza.
What it actually does
SAB Biotherapeutics develops a special type of medicine called human polyclonal immunotherapeutic antibodies. Think of antibodies as your body's natural defense system against sickness. SAB's approach uses genetically engineered cattle to produce these antibodies, which are then used to treat diseases. This method aims to create targeted, potent therapies without needing to rely on human donors. The company's technology platform is called DiversitAb™, and it's designed to rapidly develop these antibody-based treatments for various diseases.
SAB-142 for Type 1 Diabetes
The company's main focus is on developing SAB-142, a potential treatment for Type 1 Diabetes (T1D). T1D is an autoimmune disease where the body's immune system mistakenly attacks the cells that produce insulin. SAB-142 is designed to be a disease-modifying immunotherapy, meaning it aims to address the underlying cause of the disease rather than just managing symptoms. The goal is to potentially delay the onset and slow the progression of T1D, preserving the body's ability to produce insulin. This candidate is currently in Phase 2b clinical trials, which are a crucial stage of testing to evaluate its effectiveness and safety in a larger group of patients.
What management is betting on now
SAB Biotherapeutics is heavily focused on advancing its lead product candidate, SAB-142, through the necessary clinical trials to gain regulatory approval. They are also exploring the potential of their DiversitAb™ platform to develop other novel therapeutic candidates for a range of immune and autoimmune disorders. The company's strategy involves leveraging its unique technology to create differentiated treatments that address significant unmet medical needs, aiming to transform the treatment landscape for patients with serious diseases.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
FY2024 Q3
$-6.39M
FY2024 Q4
$-9.59M
FY2025 Q4
$-17.71M
FY2026 Q1
$-15.25M
FY2026 Q2
$-11.43M
Revenue
—
Net income
$-22.49M
Diluted EPS
-0.28
Operating cash flow
$-9.84M
Free cash flow
$-11.43M
Fetching…
Sources
Revenue
—
Net income
$-18.87M
Diluted EPS
-0.35
Operating cash flow
$-14.27M
Free cash flow
$-15.25M
Fetching…
Sources
Revenue
$0.00
Net income
$-16.86M
Diluted EPS
1.07
Operating cash flow
$-16.78M
Free cash flow
$-17.71M
Fetching…
Sources
Revenue
—
Net income
$45.45M
Diluted EPS
-0.21
Operating cash flow
$-13.05M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-10.11M
Diluted EPS
-1.09
Operating cash flow
$-7.15M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-5.20M
Diluted EPS
-0.56
Operating cash flow
$-7.80M
Free cash flow
—
Fetching…
Sources
Revenue
$-148.44K
Net income
$-11.39M
Diluted EPS
-1.23
Operating cash flow
$-9.53M
Free cash flow
$-9.59M
Fetching…
Sources
Revenue
$263.14K
Net income
$-10.35M
Diluted EPS
-1.12
Operating cash flow
$-6.29M
Free cash flow
$-6.39M
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $2.53
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $97.5M - more cash than debt. Interest coverage -203.4x.
Net debt
$-97.50M
Interest coverage
-203.41x
SAB Biotherapeutics, Inc.'s profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 4 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.
Healthy
Worse cushion
Baseline
Better cushion
SABS
BASELINE
SAB Biotherapeutics, Inc.
Total debt $5.13M Interest coverage -203.41x This is the baseline the peer rows are being compared against.
Total debt $2.88M Interest coverage -63.33x Neither company has much profit cushion over interest right now.
Total debt $16.42M Interest coverage -192.41x Neither company has much profit cushion over interest right now.
Total debt $112.32M Interest coverage -8.69x Neither company has much profit cushion over interest right now.
Total debt $2.07M Interest coverage -10.88x Neither company has much profit cushion over interest right now.
What you should know
The case for and against SABS
0 Rewards
2 Risks
Rewards
Risks
-
Insider ownership is only 0.7% (peer median: 12.5%).
-
Return on equity was -11.3% last year — the company lost money on shareholders' equity.
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-2.65x
P/B
0.98x
P/S
—
EV/EBITDA
-2.01x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
ROE
-11.3%
ROA
-33.5%
Health
Liquidity and balance-sheet strength
Debt / equity
0.02x
Current ratio
9.22x
Quick ratio
8.93x
Total debt
$5.13M
Total cash
$102.63M
Growth
How the business has been compounding
Revenue TTM
$377.83K
Revenue 5Y CAGR
—
EPS TTM
-1.29
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-53.94M
Free CF TTM
$-45.71M
FCF margin
-12,097.4%
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
0.0%
Last ex-div date
—